<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Roche acquire US based pharmaceutical company Promedior	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/roche-acquire-us-based-promedior/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/roche-acquire-us-based-promedior/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Tue, 21 Jan 2020 15:00:05 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>
	<item>
		<title>
		By: Consort Medical shares dip following modest update - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/roche-acquire-us-based-promedior/#comment-13786</link>

		<dc:creator><![CDATA[Consort Medical shares dip following modest update - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 21 Jan 2020 15:00:05 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24020#comment-13786</guid>

					<description><![CDATA[[&#8230;] Analysts in the market considered the nature of the proposed £505 million deal, following the move by Swiss rival Rocge Holding Ltd (SWX: ROG) taking over US firm Promedior. [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] Analysts in the market considered the nature of the proposed £505 million deal, following the move by Swiss rival Rocge Holding Ltd (SWX: ROG) taking over US firm Promedior. [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: Roche completes $4.3 billion takeover of Spark Therapeutics - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/roche-acquire-us-based-promedior/#comment-13262</link>

		<dc:creator><![CDATA[Roche completes $4.3 billion takeover of Spark Therapeutics - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 17 Dec 2019 13:23:39 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24020#comment-13262</guid>

					<description><![CDATA[[&#8230;] The deal is valued at $4.3 billion and the deal has been formally completed following clearance from the British and US competition authors, and becomes Roche&#8217;s second acquisition in a short space of time following the recent deal with US based Promedior. [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] The deal is valued at $4.3 billion and the deal has been formally completed following clearance from the British and US competition authors, and becomes Roche&#8217;s second acquisition in a short space of time following the recent deal with US based Promedior. [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: SkinBioTherapeutics shares fall following widened loss reports - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/roche-acquire-us-based-promedior/#comment-12818</link>

		<dc:creator><![CDATA[SkinBioTherapeutics shares fall following widened loss reports - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 26 Nov 2019 15:10:22 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24020#comment-12818</guid>

					<description><![CDATA[[&#8230;] Roche (SWX: ROG) announced the acquisition of US drugmaker Promedior last [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] Roche (SWX: ROG) announced the acquisition of US drugmaker Promedior last [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
